Cargando…
Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence
With the lack of effective therapy, chemoprevention and vaccination, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Interestingly, montelukast, a drug usually used in asthma, may be proposed as a potential adjuvant therapy in COVID-19. The aim of the pres...
Autores principales: | Barré, Jean, Sabatier, Jean-Marc, Annweiler, Cédric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500361/ https://www.ncbi.nlm.nih.gov/pubmed/33013375 http://dx.doi.org/10.3389/fphar.2020.01344 |
Ejemplares similares
-
Point of view: Should COVID-19 patients be supplemented with vitamin D?
por: Annweiler, Cédric, et al.
Publicado: (2020) -
Montelukast and Acute Coronary Syndrome: The Endowed Drug
por: Alomair, Basil Mohammed, et al.
Publicado: (2022) -
Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients
por: Camera, Marina, et al.
Publicado: (2022) -
Montelukast Improves Symptoms and Lung Function in Asthmatic Women Compared With Men
por: Esposito, Renata, et al.
Publicado: (2019) -
Montelukast Use Decreases Cardiovascular Events in Asthmatics
por: Hoxha, Malvina, et al.
Publicado: (2021)